BioCentury
ARTICLE | Translation in Brief

A window to IBD

Oncostatin M: a new biomarker and target in IBD

May 4, 2017 7:27 PM UTC

An academia-industry collaboration has identified the cytokine oncostatin M (OSM) as possibly the first biomarker for predicting whether a patient with inflammatory bowel disease (IBD) will respond to anti-tumor necrosis factor α (TNFα) therapy.

In a Nature Medicine study published last month, researchers from the University of Oxford, RWTH Aachen University and the Janssen R&D unit of Johnson & Johnson (NYSE:JNJ) analyzed cytokine expression in tissue samples from intestinal mucosal biopsies of patients in clinical trials of J&J's anti-TNFα therapies. The pharma markets Remicade infliximab and Simponi golimumab for IBD, as well as other inflammatory diseases...